RESUMEN
PURPOSE OF THE STUDY: to analyze the expression of markers of apoptosis and proliferation in patients with ulcerative colitis. MATERIALS AND METHODS: in 80 patients with ulcerative colitis the analysis of expression of apoptosis marker BAX and proliferation marker Ki-67, as well as the cell cycle regulator p53 in biopsy materials of the mucous membrane of the colon was carried out. THE RESULTS: decreased cell proliferative activity and increase of the apoptosis rate depending on the severity, the localization of the inflammatory process and its endoscopic activity were registered.
Asunto(s)
Apoptosis , Colitis Ulcerosa , Regulación de la Expresión Génica , Proteína p53 Supresora de Tumor/biosíntesis , Proteína X Asociada a bcl-2/biosíntesis , Adolescente , Adulto , Anciano , Biomarcadores/metabolismo , Biopsia , Proliferación Celular , Colitis Ulcerosa/diagnóstico , Colitis Ulcerosa/metabolismo , Colitis Ulcerosa/patología , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: Drug-drug interactions (DDIs) in the treatment of chronic hepatitis C infection became a potential challenge with the introduction of direct-acting anti-virals (DAAs). Both currently approved DAAs, the protease inhibitors (PIs) telaprevir (TVR) and boceprevir (BOC), are substrates and inhibitors of P-glycoprotein and the cytochrome P450 3A4, which are regularly involved in DDIs. AIM: To analyse the risk for DDIs in patients with chronic HCV genotype 1 infection considered for PI treatment at a tertiary referral centre. METHODS: The first 115 consecutive patients selected for a PI therapy at Hannover Medical School were included. All changes to co-medication before and during PI treatment were documented. Drugs were checked for DDIs with TVR and BOC using DDI websites and the respective prescribing information. RESULTS: Out-patient medication contained 116 different drugs. Median number of drugs/patient was 2 (range 0-11). The risk for DDIs was substantial for 38% of the drugs affecting 49% of patients. Only 4% of the drugs were strictly contraindicated. DDIs between a PI and drugs newly prescribed during anti-viral therapy were considerable in 42% of the patients. Suspected DDIs were managed by dose adjustments and discontinuation of co-medication in 7% and 21% of the patients respectively. CONCLUSIONS: Many patients with chronic HCV genotype 1 infection are affected by potential DDIs if treated with a protease inhibitor, but only in a minority of cases co-medication is strictly incompatible. Overall, the challenge of DDIs is time-consuming, but well manageable by a careful review of the patient's drug chart and monitoring during treatment.
Asunto(s)
Antivirales/administración & dosificación , Hepatitis C Crónica/tratamiento farmacológico , Oligopéptidos/administración & dosificación , Prolina/análogos & derivados , Inhibidores de Proteasas/administración & dosificación , Adulto , Anciano , Estudios de Cohortes , Interacciones Farmacológicas , Quimioterapia Combinada , Femenino , Hepatitis C Crónica/virología , Humanos , Masculino , Persona de Mediana Edad , Prolina/administración & dosificaciónRESUMEN
A series of new modifications of alkyl cationic glycerolipids with hetero polar domain has been synthesized. The most active compound rac-N-(4-[(2-ethoxy-3-octadecyloxy)prop-1-yloxycarbonyl]butyl)-N'-etylimidazoliyiodid in micromolar concentrations causes a delay of cell cycle in phase G1, DNA fragmentation and apoptosis of cell line leukemia.